CN103119059B - 针对人抗苗勒管激素ii型受体的新的突变型人源化12g4抗体及其片段 - Google Patents

针对人抗苗勒管激素ii型受体的新的突变型人源化12g4抗体及其片段 Download PDF

Info

Publication number
CN103119059B
CN103119059B CN201180032211.8A CN201180032211A CN103119059B CN 103119059 B CN103119059 B CN 103119059B CN 201180032211 A CN201180032211 A CN 201180032211A CN 103119059 B CN103119059 B CN 103119059B
Authority
CN
China
Prior art keywords
seq
antibody
monoclonal antibody
sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180032211.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103119059A (zh
Inventor
C·拜赫伦斯
I·纳瓦罗-特隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
French Laboratory For Fractionation And Biotechnology Corp
NATIONAL HEALTH AND MEDICINE INST
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
LFB Biotechnologies SAS
Universite de Montpellier
National Cancer Center Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, LFB Biotechnologies SAS, Universite de Montpellier, National Cancer Center Korea filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of CN103119059A publication Critical patent/CN103119059A/zh
Application granted granted Critical
Publication of CN103119059B publication Critical patent/CN103119059B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
CN201180032211.8A 2010-05-12 2011-04-01 针对人抗苗勒管激素ii型受体的新的突变型人源化12g4抗体及其片段 Active CN103119059B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1053712A FR2959994B1 (fr) 2010-05-12 2010-05-12 Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
FR1053712 2010-05-12
PCT/FR2011/050745 WO2011141653A1 (fr) 2010-05-12 2011-04-01 Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii

Publications (2)

Publication Number Publication Date
CN103119059A CN103119059A (zh) 2013-05-22
CN103119059B true CN103119059B (zh) 2016-06-29

Family

ID=43413855

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180032211.8A Active CN103119059B (zh) 2010-05-12 2011-04-01 针对人抗苗勒管激素ii型受体的新的突变型人源化12g4抗体及其片段

Country Status (11)

Country Link
US (2) US9012607B2 (https=)
EP (1) EP2569333B1 (https=)
JP (2) JP6043998B2 (https=)
CN (1) CN103119059B (https=)
AR (1) AR081159A1 (https=)
BR (1) BR112012028859B1 (https=)
CA (1) CA2798336C (https=)
DK (1) DK2569333T3 (https=)
ES (1) ES2661080T3 (https=)
FR (1) FR2959994B1 (https=)
WO (1) WO2011141653A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016576A1 (en) 2011-07-26 2013-01-31 United Parcel Service Of American, Inc. Systems and methods for managing fault codes
FR2984750B1 (fr) 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
US10509035B2 (en) * 2015-08-07 2019-12-17 Gamamabs Pharma Sa Antibodies, antibody drug conjugates and methods of use
WO2017079303A1 (en) * 2015-11-02 2017-05-11 The Cleveland Clinic Foundation Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
FR3060394B1 (fr) * 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
KR20200014276A (ko) 2017-04-14 2020-02-10 가마맵스 파마 암을 예방 또는 치료하기 위한 amhrii-결합 화합물
US20230227566A1 (en) * 2017-04-14 2023-07-20 Gamamabs Pharma Amhrii-binding compounds for preventing or treating lung cancers
CN111108123A (zh) * 2017-05-29 2020-05-05 加马玛布斯制药公司 癌症相关的免疫抑制抑制剂
EP3789401A1 (en) 2019-09-03 2021-03-10 Gamamabs Pharma Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers
EP3812008A1 (en) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
WO2021155295A1 (en) * 2020-01-31 2021-08-05 The Cleveland Clinic Foundation Anti-müllerian hormone receptor 2 antibodies and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506358A (zh) * 2006-05-15 2009-08-12 免疫医学股份有限公司 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物
CN101573382A (zh) * 2006-11-02 2009-11-04 法国国家健康医学研究院 针对人抗苗勒激素ⅱ型受体（amhr-ⅱ）的单克隆抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216864A1 (en) * 2000-12-21 2002-07-01 Mcgill University Conjugates of antibodies and anticancer drugs
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005005615A2 (en) * 2003-07-08 2005-01-20 Fox Chase Cancer Center Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer
CA2631327C (en) * 2005-12-02 2015-10-13 Genentech, Inc. Her2 binding polypeptides and uses thereof
WO2007117657A2 (en) * 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506358A (zh) * 2006-05-15 2009-08-12 免疫医学股份有限公司 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物
CN101573382A (zh) * 2006-11-02 2009-11-04 法国国家健康医学研究院 针对人抗苗勒激素ⅱ型受体（amhr-ⅱ）的单克隆抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Directed Evolution, Phage Display and Combination of Evolved Mutants: A Strategy to Recover the Neutralization Properties of the scFv Version of BCF2 a Neutralizing Monoclonal Antibody Specific to Scorpion Toxin Cn2;V. R. Jua´rez-Gonza´ lez,et al.;《J.MOL.BIOL.》;20051231;第346卷;第1287-1297页，尤其是摘要 *
Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning;Qing-An Yuan,et al.;《Cancer immunolol immunother》;20080804;第57卷;第367-378页，尤其是摘要 *
抗苗勒管激素与卵巢功能;张莉莉等;《中国妇幼健康研究》;20061231;第17卷(第6期);第507-510页 *

Also Published As

Publication number Publication date
FR2959994A1 (fr) 2011-11-18
JP2017029139A (ja) 2017-02-09
JP2013534408A (ja) 2013-09-05
BR112012028859A8 (pt) 2017-12-05
ES2661080T3 (es) 2018-03-27
BR112012028859B1 (pt) 2022-02-22
CA2798336A1 (fr) 2011-11-17
FR2959994B1 (fr) 2012-08-24
US20150232563A1 (en) 2015-08-20
CN103119059A (zh) 2013-05-22
EP2569333A1 (fr) 2013-03-20
CA2798336C (fr) 2018-08-21
BR112012028859A2 (https=) 2017-08-15
JP6043998B2 (ja) 2016-12-14
WO2011141653A1 (fr) 2011-11-17
JP6435295B2 (ja) 2018-12-05
AR081159A1 (es) 2012-07-04
DK2569333T3 (en) 2018-03-26
EP2569333B1 (fr) 2017-12-13
US20130136743A1 (en) 2013-05-30
US9637544B2 (en) 2017-05-02
US9012607B2 (en) 2015-04-21

Similar Documents

Publication Publication Date Title
CN103119059B (zh) 针对人抗苗勒管激素ii型受体的新的突变型人源化12g4抗体及其片段
JP7854016B2 (ja) 腫瘍治療薬及びその応用
CN113227146B (zh) 密蛋白18.2结合部分和其用途
JP6925421B2 (ja) プログラム化された細胞死蛋白質リガンド−１（ｐｄ−ｌ１）に対する抗体及びその用途
EP2262836B1 (en) Antibody against the csf-1 r
JP5996558B2 (ja) Ｃｓｆ−１ｒに対する抗体
EP3998283A1 (en) Antibody binding specifically to b7-h3 and use thereof
CN110799546B (zh) 重组双特异性抗体
WO2022078523A1 (zh) 抗体药物偶联物及其应用
TW202208438A (zh) 抗ｌｉｌｒｂ１抗體或其抗原結合片段、製備其的方法、藥物組成物、核酸分子、重組載體以及重組細胞
EP4714978A1 (en) Antibody targeting dll3 and use of antibody
CN113272322A (zh) 神经内分泌癌靶向治疗
US20230374151A1 (en) Anti-tn-muc1 chimeric antigen receptors
EP4144764A1 (en) TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN
WO2024114410A1 (zh) 靶向gpc3的抗体及其用途
HK40054516B (zh) 新的间皮素抗体和包含其的组合物
WO2023246574A1 (zh) 靶向gpc3的抗体及其用途
HK40066220B (zh) 一种人源化vegfr2抗体及其应用
HK40066220A (zh) 一种人源化vegfr2抗体及其应用
HK40066232A (zh) 一种人源化抗vegfr2抗体及其应用
HK40066232B (zh) 一种人源化抗vegfr2抗体及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: FRENCH LABORATORY FOR FRACTIONATION AND BIOTECHNOL

Free format text: FORMER OWNER: LFB BIOTECHNOLOGIES

Effective date: 20140120

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140120

Address after: France Levin foruris

Applicant after: French Laboratory For Fractionation and Biotechnology Corp.

Applicant after: Universite Montpellier 1

Applicant after: Inst Nat Sante Rech Med

Applicant after: National Health and Medicine Inst.

Address before: France Levin foruris

Applicant before: Univ Montpellier I

Applicant before: Universite Montpellier 1

Applicant before: Inst Nat Sante Rech Med

Applicant before: National Health and Medicine Inst.

C14 Grant of patent or utility model
GR01 Patent grant
CP02 Change in the address of a patent holder

Address after: French pitot

Patentee after: LFB BIOTECHNOLOGIES

Patentee after: Universite Montpellier I

Patentee after: Guo Jiakangaizhongxin

Patentee after: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE)

Address before: France Levin foruris

Patentee before: LFB BIOTECHNOLOGIES

Patentee before: Universite Montpellier I

Patentee before: Guo Jiakangaizhongxin

Patentee before: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE)

CP02 Change in the address of a patent holder